NasdaqGS:GRAB
NasdaqGS:GRABTransportation

Grab Holdings And 2 Promising Penny Stocks For Your Watchlist

As the U.S. stock market navigates a volatile period, marked by fluctuations in major indices and record highs in gold prices, investors are increasingly exploring diverse opportunities to mitigate risks and enhance their portfolios. Penny stocks, though considered a niche area of investment today, continue to offer intriguing possibilities for growth by focusing on smaller or newer companies with potential upside. In this article, we will examine three penny stocks that demonstrate strong...
NYSE:YALA
NYSE:YALAInteractive Media and Services

Undiscovered Gems in the US Market to Watch This January 2026

As the U.S. stock market experiences a rebound with major indices like the Dow and S&P 500 closing higher due to eased geopolitical tensions, investors are keenly observing small-cap stocks for potential opportunities. In this dynamic environment, identifying promising stocks often involves looking for companies that can navigate economic shifts and capitalize on emerging trends, making them potential gems in the current market landscape.
NYSE:COUR
NYSE:COURConsumer Services

Is Andrew Ng’s India AI Upskilling Push Quietly Reframing Coursera’s (COUR) Long-Term Platform Ambition?

In recent days, comments from Coursera co-founder Andrew Ng about the urgent need for AI upskilling in India highlighted risks of job disruption amid rapid AI adoption. His warning also underscored a potential opening for online education platforms like Coursera as enterprises and workers seek scalable AI training and governance solutions. We will explore how Ng’s emphasis on large-scale AI upskilling in India influences Coursera’s investment narrative and perceived long-term positioning...
NasdaqGS:RXRX
NasdaqGS:RXRXBiotechs

Is Recursion (RXRX) Turning Nvidia-Backed AI Hype Into a Durable Drug Discovery Advantage?

Recent commentary on Recursion Pharmaceuticals has highlighted its AI-driven drug discovery platform, including the BioHive-2 supercomputer and the Recursion OS, alongside its collaboration with Nvidia and a cash runway that management indicates extends through 2027. Analyst optimism and insider share purchases have reinforced investor attention on Recursion’s attempt to fuse biology, automation, and advanced computing into a differentiated approach to pharmaceutical development. Against...
NasdaqGS:FLEX
NasdaqGS:FLEXElectronic

A Look At Flex (FLEX) Valuation After Tariff Relief Lifts Trade Sentiment

Flex (FLEX) drew attention after the U.S. administration suspended planned tariffs on European allies, easing fears of a trade conflict as positive commentary on trade relations coincided with a 4.1% intraday share move. See our latest analysis for Flex. That tariff relief comes after a strong run for investors, with Flex’s 1-year total shareholder return of 47.59% and a very large 5-year total shareholder return of 381.73% contrasting with a flatter 30-day share price return of 1.54% and...
NYSE:ELAN
NYSE:ELANPharmaceuticals

Elanco Animal Health (ELAN) Valuation Check After Analyst Upgrades And New Product Approvals

Elanco Animal Health (ELAN) is back on investors’ radar after a cluster of analyst upgrades and fresh regulatory approvals, including USDA clearance for Befrena and conditional FDA approval for Credelio Quattro. See our latest analysis for Elanco Animal Health. Those approvals and analyst upgrades have arrived alongside a clear upswing in market sentiment, with a recent 12.1% 1 month share price return and a very large 1 year total shareholder return that together point to building momentum...
NYSE:AI
NYSE:AISoftware

C3.ai’s FedRAMP Win Tests Turnaround Hopes In Government AI Markets

C3.ai (NYSE:AI) has secured FedRAMP authorization for its AI platform, approving it for use in sensitive U.S. federal government environments. The company has won new contracts with the U.S. Army to develop AI driven logistics capabilities. C3.ai also gained a contract with the Department of Health and Human Services to build a unified data foundation for health related initiatives. C3.ai is pushing deeper into the federal market at a time when its share price, recently at $12.97, reflects...